

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 1. Health State Probabilities for Arteriovenous Fistula Markov Models

	65-69 age group		70-74 age group		75-79 age group		80-84 age group		85-89 age group	
Health States	8 months	60 months	8 months	60 months	8 months	60 months	8 months	60 months	8 months	60 months
75th percentile										
AVG	48.1%	11.2%	46.5%	9.3%	43.8%	6.7%	39.2%	3.7%	32.2%	1.3%
CVC	41.3%	34.7%	39.2%	25.2%	35.5%	14.1%	29.9%	5.2%	21.8%	0.9%
Death	10.6%	54.2%	14.3%	65.5%	20.7%	79.2%	30.9%	91.1%	46.0%	97.8%
50th percentile										
AVG	46.5%	9.2%	43.6%	6.5%	38.9%	3.5%	31.0%	1.1%	16.7%	----
CVC	39.0%	24.8%	35.3%	13.5%	29.4%	4.8%	20.6%	0.7%	7.3%	----
Death	14.5%	66.0%	21.1%	80.0%	31.7%	91.7%	48.4%	98.2%	76.0%	100%
25th percentile										
AVG	41.1%	4.8%	35.7%	2.2%	26.3%	0.4%	17.2%	----	4.2%	----
CVC	32.2%	7.9%	25.7%	2.3%	15.7%	0.2%	7.8%	----	0.7%	----
Death	26.7%	87.3%	38.6%	95.5%	58.0%	99.4%	75%	100%	95.1%	100%

Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter.

Data shown is probability of AVF use, CVC use, or death at 8 months (after up to two attempts at AVF placement) and 60 months after dialysis initiation for all age and life expectancy groups. Cells with dashes indicate values approaching 0%.

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 2. Health State Probabilities for Arteriovenous Graft Markov Models


	65-69 age group		70-74 age group		75-79 age group		80-84 age group		85-89 age group	
Health States	3 months	60 months	3 months	60 months	3 months	60 months	3 months	60 months	3 months	60 months
75th percentile										
AVG	53.5%	7.0%	52.9%	5.5%	39.3%	3.6%	49.8%	1.6%	46.4%	0.4%
CVC	42.1%	35.5%	41.1%	25.4%	51.8%	13.7%	36.3%	4.6%	31.3%	0.7%
Death	4.4%	57.5%	6.0%	69.1%	8.9%	82.7%	13.9%	93.8%	22.2%	98.9%
50th percentile										
AVG	52.9%	5.5%	51.7%	3.4%	49.7%	1.5%	45.8%	0.3%	36.3%	----
CVC	41.0%	24.9%	39.1%	13.1%	36.0%	4.2%	30.5%	0.5%	18.6%	----
Death	6.1%	69.6%	9.2%	83.5%	14.3%	94.3%	23.7%	99.2%	45.1%	100%
25th percentile										
AVG	50.6%	2.3%	48.1%	0.8%	43.1%	0.1%	44.1%	----	20.6%	----
CVC	37.5%	7.3%	33.9%	1.9%	26.9%	0.1%	36.8%	----	4.9%	----
Death	11.9%	90.4%	18.0%	97.3%	30.0%	99.8%	19.1%	100%	74.4%	100%

Abbreviations: AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter.

Data shown is probability of using AVG for hemodialysis, CVC use (before AVG can be used or after AVG experiences compromised patency or infection), or death at 3 months (after up to two attempts at AVG placement) and 60 months after dialysis initiation for all age and life expectancy groups. Cells with dashes indicate values approaching 0%.

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Figure 1. Cost-Effectiveness Acceptability Curves



Cost-effectiveness acceptability curve for AVF placement, AVG placement, or continued CVC use in the 65-69 year old age group in the highest quartile of life-expectancy (a) and the 85-89 year old age group in the lowest quartile of life-expectancy (b). Willingness-to-pay represents the amount of dollars society is willing to pay for 1 quality adjusted life year. The probability that the incremental cost-effectiveness ratio is at or below the willingness-to-pay threshold is on the Y axis.